Expert Video Report on Gastric Cancer

ESMO 2018 Congress

Speaker: Florian Lordick

Commenting on the findings from TAGS, ATTRACTION-2 and a pooled analysis of 4 randomised clinical trials presented at ESMO 2018 Congress, Dr. Florian Lordick says that interesting results were presented about 3rd line treatment in advanced gastric cancer and gender differences in terms of therapy efficacy and toxicity.
According to Dr. Lordick, the treatment landscape is changing and we now have effective treatment options for 3rd line advanced gastric cancer. Special attention should be payed to gender differences in studies and clinical practice as women may be more prone and need more supportive treatments to compensate for higher observed toxicity.

ESMO 2018 Congress abstracts: